gt101
Cell therapyexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 5, 2021 (NCT06077903)
Timeline
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06241781 | Phase 2 | Apr 2, 2024 | Grit Biotechnology |
| NCT05430373 | Phase 1 | May 23, 2022 | Grit Biotechnology |
| NCT06077903 | Early Phase 1 (Phase 1) | Jul 5, 2021 | Grit Biotechnology |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Grit Biotechnology | For profit | 3 | 3 | 2 | 2021 |
1 organizations
Page 1 / 1